Molecule of the Week


March 3, 2008

Lisdexamfetamine—trade name Vyvanse—is amphetamine coupled with l-lysine. It is being developed to treat attention-deficit hyperactivity disorder (ADHD) in pediatric patients. It provides controlled release of amphetamine via hydrolysis within the body and decreases the potential for abuse because crushing the capsule does not accelerate its activation.